Innate Pharma S.A.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Innate Pharma S.A. generated cash of -$32,558,000, which is less than the previous year. Cash used in financing activities reached the amount of -$1,966,000 last year. Net change in cash is therefore -$13,620,000.
Cash Flow
| 2014 | -18.13M | -3.82M | 47.95M |
|---|---|---|---|
| 2015 | 207.91M | -122.29M | 3.03M |
| 2016 | -36.85M | 60.51M | -602K |
| 2017 | -48.06M | -29.46M | 915K |
| 2018 | -32.53M | 24.27M | 61.22M |
| 2019 | 34.92M | -62.12M | 77.76M |
| 2020 | -51.80M | -13.37M | -1.13M |
| 2021 | -58.45M | -917K | 26.81M |
| 2022 | -19.15M | 1.87M | -1.82M |
| 2023 | -32.55M | 20.63M | -1.96M |
IPHA Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 84.22M | 103.75M | 136.79M | 202.88M | 152.31M | 99.36M | 175.90M | 152.87M | 64.28M | 38.36M |
Operating activities | ||||||||||
Net income | -7.57M | -58.10M | -52.80M | -63.98M | -20.75M | 3.04M | -48.38M | 12.64M | -6.70M | -19.64M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 5.09M | 45.40M | 4.59M | 56.79M | 16.52M | 7.40M | 4.39M | 3.26M | 2.65M | 2.34M |
Stock-based compensation expense | 4.25M | 4.24M | 2.61M | 2.47M | 3.82M | 0 | 9.82M | 1.03M | 1.01M | 377K |
| Deferred income tax benefit | 4.25M | 4.24M | 2.61M | 2.47M | 3.82M | 0 | 9.82M | 1.03M | 1.01M | 377K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | -4.20M | 3.39M | -22.91M | 110.29M | -130.69M | 10.97M | -16.17M | -6.14M | -2.07M |
Inventories | 0 | 0 | -6.27M | 25.38M | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -3.89M | -7.66M | -946K | -6.52M | 1.38M | 34.33M | 4.38M | 7.88M | 9.23M | 1.65M |
Cash generated by operating activities | -32.55M | -19.15M | -58.45M | -51.80M | 34.92M | -32.53M | -48.06M | -36.85M | 207.91M | -18.13M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | -3M | 0 | 0 | -43.27M | -18.15M | -121.86M | -1.96M |
Investments In Property Plant And Equipment | -351K | -1.12M | -1.33M | -11.28M | -65.40M | -1.42M | -6.02M | -9.39M | -7.39M | -2.34M |
Acquisitions Net | 0 | 0 | 7K | 9K | 0 | 22K | 3.06M | 8.04M | 0 | -60K |
Cash generated by investing activities | 20.63M | 1.87M | -917K | -13.37M | -62.12M | 24.27M | -29.46M | 60.51M | -122.29M | -3.82M |
Financing activities | ||||||||||
Common Stock Issued | 395K | 198K | 499K | 49K | 66.00M | 62.55M | 491K | 14K | 125K | 47.78M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -70K |
Repayments of term debt | -2.36M | -2.02M | -2.06M | -2.20M | 11.91M | -1.34M | 537K | -685K | -452K | -613K |
Cash used in financing activities | -1.96M | -1.82M | 26.81M | -1.13M | 77.76M | 61.22M | 915K | -602K | 3.03M | 47.95M |
Net Change In Cash | -13.62M | -19.53M | -33.03M | -66.09M | 50.57M | 52.94M | -76.53M | 23.03M | 88.58M | 25.92M |
Cash at end of period | 70.60M | 84.22M | 103.75M | 136.79M | 202.88M | 152.31M | 99.36M | 175.90M | 152.87M | 64.28M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |